The effect of probiotics on Clostridium difficile diarrhea

American Journal of Gastroenterology

Volumn 95, Issue 1 SUPPL., 2000, Pages

  Pochapin, Mark ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ERYTHROMYCIN; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; VANCOMYCIN; YOGHURT;

BIFIDOBACTERIUM; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; HUMAN; INTESTINE FLORA; LACTOBACILLUS CASEI; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; SACCHAROMYCES BOULARDII;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; LACTOBACILLUS; PROSPECTIVE STUDIES; RECURRENCE; YOGURT;

EID: 0033985298     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00809-6     Document Type: Conference Paper

References (12)

1. Gorbach S.L., Chang T.W., Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet. 2:1987;1519. (letter).
2. McFarland L.V., Mulligan M.E., Kwok R.Y., et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 320:1989;204-210.
3. Kelly C.P., Pothoulakis C., LaMont J.T. Clostridium difficile colitis. N Engl J Med. 330:1994;257-262.
4. Riley T.V., Codde J.P., Rouse I.L. Increased length of hospital stay due to Clostridium difficile-associated diarrhoea. Lancet. 345:1995;455-456. (letter).
5. Macgowan A.P., Brown I., Feeney R., et al. Clostridium difficile-associated diarrhoea and length of hospital stay. J Hosp Infect. 31:1995;241-244. (letter).
6. Fekety R., McFarland L.V., Surawicz C.M., et al. Recurrent Clostridium difficile diarrhea Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial . Clin Infect Dis. 24:1997;324-333.
7. Colombel J.F., Cortot A., Neut C., et al. Yoghurt with Bifidobacterium longum reduces erythromycin-induced gastrointestinal effects. Lancet. 2:1987;43. (letter).
8. Seal D., Borriello S.P., Barclay F., et al. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microb. 6:1987;51-53. (letter).
9. Surawicz C.M., Elmer G.W., Speelman P., et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii A prospective study . Gastroenterology. 96:1989;981-988. (letter).
10. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 271:1994;1913-1918.
11. Biller J.A., Katz A.J., Flores A.F., et al. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr. 21:1995;224-226.
12. Bennett R.G., Gorbach S.L., Goldin B.R., et al. Treatment of relapsing Clostridium difficile diarrhea with Lactobacillus GG. Nutrition Today. 31:(suppl 1):1996;35S-38S.